Praxis precision medicines provides corporate update and reports fourth quarter and full year 2022 financial results

Ulixacaltamide (prax-944) phase 2b essential1 study topline results for essential tremor expected in 1q23; praxis to enter quiet period following market close on thursday, february 9

PRAX Ratings Summary

PRAX Quant Ranking